Now showing items 1-15 of 15

    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. 

      Phi, X-A; Houssami, N; Hooning, MJ; Riedl, CC; Leach, MO; Sardanelli, F; Warner, E; Trop, I; Saadatmand, S; Tilanus-Linthorst, MMA; Helbich, TH; van den Heuvel, ER; de Koning, HJ; Obdeijn, I-M; de Bock, GH (2017-11)
      INTRODUCTION: Women with a strong family history of breast cancer (BC) and without a known gene mutation have an increased risk of developing BC. We aimed to investigate the accuracy of screening using annual mammography ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Circulating tumor DNA-From bench to bedside. 

      Lim, JSJ; Janku, F; Yap, TA (2017-05)
      In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may ...
    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. 

      Eccleston, A; Bentley, A; Dyer, M; Strydom, A; Vereecken, W; George, A; Rahman, N (2017-04)
      OBJECTIVES: To evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed "BRCA") testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first- and ...
    • Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. 

      Lawler, M; Alsina, D; Adams, RA; Anderson, AS; Brown, G; Fearnhead, NS; Fenwick, SW; Halloran, SP; Hochhauser, D; Hull, MA; Koelzer, VH; McNair, AGK; Monahan, KJ; Näthke, I; Norton, C; Novelli, MR; Steele, RJC; Thomas, AL; Wilde, LM; Wilson, RH; Tomlinson, I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative (2018-01)
      OBJECTIVE: Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN: RG analysis was ...
    • Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. 

      Johns, LE; Coleman, DA; Swerdlow, AJ; Moss, SM (2017-01-17)
      BACKGROUND: Population breast screening has been implemented in the UK for over 25 years, but the size of benefit attributable to such programmes remains controversial. We have conducted the first individual-based cohort ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      INTRODUCTION: Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology. SOURCES OF DATA: ...
    • National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. 

      Brizmohun Appayya, M; Adshead, J; Ahmed, HU; Allen, C; Bainbridge, A; Barrett, T; Giganti, F; Graham, J; Haslam, P; Johnston, EW; Kastner, C; Kirkham, APS; Lipton, A; McNeill, A; Moniz, L; Moore, CM; Nabi, G; Padhani, AR; Parker, C; Patel, A; Pursey, J; Richenberg, J; Staffurth, J; van der Meulen, J; Walls, D; Punwani, S (2018-07)
      OBJECTIVES: To identify areas of agreement and disagreement in the implementation of multi-parametric magnetic resonance imaging (mpMRI) of the prostate in the diagnostic pathway. MATERIALS AND METHODS: Fifteen UK experts ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to ...
    • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Horwich, A; Parker, C; Bangma, C; Kataja, V (2010-05)
    • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Horwich, A; Parker, C; de Reijke, T; Kataja, V (2013-10)
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01)
      BACKGROUND: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. 

      Otto, SJ; Moss, SM; Määttänen, L; Roobol, M; Zappa, M; Nelen, V; Kwiatkowski, M; Villers, A; Hugosson, J; Sanchez, AB; de Koning, HJ (2010-11)
      BACKGROUND: To describe the variation in PSA level by age group and screening round in the ERSPC centres and the variation in cancer detection rates in relation to the underlying prostate cancer incidence. METHODS: Individual ...
    • The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. 

      Noujaim, J; Jones, RL; Swansbury, J; Gonzalez, D; Benson, C; Judson, I; Fisher, C; Thway, K (2017-02-28)
      BACKGROUND: EWSR1 rearrangements were first identified in Ewing sarcoma, but the spectrum of EWSR1-rearranged neoplasms now includes many soft tissue tumour subtypes including desmoplastic small round cell tumour (DSRCT), ...